Ligand-independent TREM-1 inhibitory peptides GF9 and GA31 (the latter in a form of macrophage-targeted lipopeptide complexes, GA31-LPC) were evaluated in animal models of pancreatic cancer, sepsis, pulmonary inflammation, and fibrosis. The gene discussed is TREM1; the disease is pancreatic neoplasm.